Provided by Tiger Fintech (Singapore) Pte. Ltd.

180 Life Sciences Corp

0.8985
+0.02132.43%
Post-market: 0.8131-0.0854-9.50%18:38 EDT
Volume:20.87K
Turnover:17.97K
Market Cap:4.66M
PE:-0.06
High:0.9000
Open:0.8620
Low:0.8130
Close:0.8772
Loading ...

Company Profile

Company Name:
180 Life Sciences Corp
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
4
Office Location:
Building 4,Suite 200,3000 El Camino Real,Palo Alto,California,United States
Zip Code:
94306
Fax:
- -
Introduction:
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

Directors

Name
Position
James N. Woody
Chief Executive Officer and Director
Lawrence Steinman
Co-Executive Chairman
Marc Feldmann
Executive Co-Chairman
Donald A. McGovern, Jr.
Director
Francis Knuettel II
Director
Larry Gold
Director
Pamela G. Marrone
Director
Russell T. Ray
Director
Teresa M. DeLuca
Director

Shareholders

Name
Position
James N. Woody
Chief Executive Officer and Director
Ozan Pamir
Chief Financial Officer and Secretary
Jonathan Rothbard
Chief Scientific Officer